GeoVax Labs, Inc. (NASDAQ:GOVX) Receives Average Rating of “Buy” from Analysts

GeoVax Labs, Inc. (NASDAQ:GOVX) has been assigned a consensus rating of “Buy” from the seven analysts that are presently covering the company, Marketbeat.com reports. Five analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $14.20.

A number of brokerages have commented on GOVX. D. Boral Capital reiterated a “buy” rating and issued a $18.00 target price on shares of GeoVax Labs in a report on Friday, January 31st. HC Wainwright reiterated a “buy” rating and issued a $8.00 price objective on shares of GeoVax Labs in a report on Friday, November 15th. Finally, Alliance Global Partners began coverage on GeoVax Labs in a research note on Monday, November 11th. They set a “buy” rating and a $15.00 target price for the company.

Institutional Investors Weigh In On GeoVax Labs

A number of institutional investors have recently modified their holdings of GOVX. Virtu Financial LLC purchased a new position in GeoVax Labs during the 3rd quarter valued at about $97,000. Citadel Advisors LLC acquired a new stake in shares of GeoVax Labs during the fourth quarter worth about $104,000. Northern Trust Corp purchased a new position in shares of GeoVax Labs in the fourth quarter valued at approximately $29,000. Finally, Geode Capital Management LLC grew its holdings in shares of GeoVax Labs by 59.0% in the fourth quarter. Geode Capital Management LLC now owns 90,139 shares of the company’s stock valued at $223,000 after purchasing an additional 33,440 shares in the last quarter. 6.09% of the stock is owned by institutional investors and hedge funds.

GeoVax Labs Stock Up 1.2 %

Shares of GOVX opened at $1.75 on Wednesday. GeoVax Labs has a 52-week low of $1.09 and a 52-week high of $11.18. The stock has a fifty day simple moving average of $2.12 and a two-hundred day simple moving average of $2.67.

About GeoVax Labs

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.